Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 0.9% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s stock price traded down 0.9% during mid-day trading on Thursday . The company traded as low as $1.05 and last traded at $1.08. Approximately 272,314 shares traded hands during trading, a decline of 77% from the average daily volume of 1,175,750 shares. The stock had previously closed at $1.09.

Analyst Upgrades and Downgrades

Several research firms have commented on TLSA. Zacks Research raised Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings cut Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Tiziana Life Sciences Price Performance

The firm’s 50-day moving average price is $1.10 and its 200 day moving average price is $1.25.

Insider Buying and Selling at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $1.00 per share, with a total value of $667,000.00. Following the completion of the acquisition, the chief executive officer owned 4,472,261 shares of the company’s stock, valued at approximately $4,472,261. This trade represents a 17.53% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have acquired 988,423 shares of company stock valued at $985,909 in the last ninety days. 39.82% of the stock is currently owned by corporate insiders.

Institutional Trading of Tiziana Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rachor Investment Advisory Services LLC bought a new position in shares of Tiziana Life Sciences during the fourth quarter worth about $25,000. Cubist Systematic Strategies LLC acquired a new position in Tiziana Life Sciences during the 1st quarter valued at about $25,000. Marshall Wace LLP acquired a new stake in shares of Tiziana Life Sciences in the second quarter valued at approximately $39,000. HRT Financial LP bought a new stake in shares of Tiziana Life Sciences during the fourth quarter valued at approximately $36,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Tiziana Life Sciences during the fourth quarter valued at approximately $59,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.